<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="As the summer drifts away, so too does the latest quarterly earnings season. Along with other equities, most marijuana stocks have already reported their most recent figures.” data-reactid=”11″>As the summer drifts away, so too does the latest quarterly earnings season. Along with other equities, most marijuana stocks have already reported their most recent figures.
Most, but not all. This week, we saw one cannabis company report, while another received a recommendation boost but also a tough reminder of how its stock has been performing lately.
Image source: Getty Images.
Canopy Growth wins a thumbs-up, but…
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The week started off quite well for Canopy Growth (NYSE: CGC). Prior to market open on Monday, it received a significant recommendation upgrade from Seaport Global, one of the investment banks tracking the stock.” data-reactid=”26″>The week started off quite well for Canopy Growth (NYSE: CGC). Prior to market open on Monday, it received a significant recommendation upgrade from Seaport Global, one of the investment banks tracking the stock.
Analyst Brett Hundley lifted his stance on Canopy Growth from neutral to buy, with a price target of $31 per share. (It closed at $24.89 on the previous trading day; its latest closing price is $23.58.) Hundley opined that the cannabis industry, in general, presents an attractive opportunity, and Canopy Growth is poised to take advantage of this.
The analyst cited the company’s portfolio of intellectual property and its research and development efforts as potential sources of value-added goods that could be attractive to the market. He was also complimentary about Canopy Growth’s balance sheet, which is seen as relatively clean compared to peers in this frequently debt-burdened sector.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Later in the week, though, Canopy Growth's major shareholder Constellation Brands (NYSE: STZ) said it would take a $54 million hit from its investment in the marijuana stock. Much of this decline came in the wake of Canopy Growth reporting its Q1 of fiscal 2020. This was a tough period in which revenue actually declined on a quarter-over-quarter basis, and the net loss was far deeper than the average analyst estimate.” data-reactid=”29″>Later in the week, though, Canopy Growth’s major shareholder Constellation Brands (NYSE: STZ) said it would take a $54 million hit from its investment in the marijuana stock. Much of this decline came in the wake of Canopy Growth reporting its Q1 of fiscal 2020. This was a tough period in which revenue actually declined on a quarter-over-quarter basis, and the net loss was far deeper than the average analyst estimate.
Since the company reported the mentioned quarter in mid-August, investor enthusiasm for the stock has weakened. The Seaport Global recommendation was certainly a boost, but that terrible Q1 performance has left a lingering bad impression. And Constellation Brands’ stark reminder that Canopy Growth has burned a big strategic investor is not helping.
Curaleaf Q2 indicates robust growth despite widened loss
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Earnings season might be vanishing in the rearview mirror, but there's still the occasional marijuana stock reporting its fundamentals. This week saw Q2 of fiscal 2019 results handed down by Curaleaf Holdings (OTC: CURLF), and although every line item was not a bright spot, investors generally liked what they saw.” data-reactid=”32″>Earnings season might be vanishing in the rearview mirror, but there’s still the occasional marijuana stock reporting its fundamentals. This week saw Q2 of fiscal 2019 results handed down by Curaleaf Holdings (OTC: CURLF), and although every line item was not a bright spot, investors generally liked what they saw.
The company’s net revenue more than tripled on a year-over-year basis, although net loss was almost five times as deep and worse than the average analyst estimate.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Yet losses in the marijuana industry are common and expected, particularly considering the expenses required to ramp up presence and footprint in most segments of this business. Curaleaf is no different, as evidenced by its recent deal to buy vaporizer cartridge maker Cura Partners. The price tag? A cool $950 million. On top of that, it’s also paying $875 million to take over dispensary operator Grassroots.” data-reactid=”34″>Yet losses in the marijuana industry are common and expected, particularly considering the expenses required to ramp up presence and footprint in most segments of this business. Curaleaf is no different, as evidenced by its recent deal to buy vaporizer cartridge maker Cura Partners. The price tag? A cool $950 million. On top of that, it’s also paying $875 million to take over dispensary operator Grassroots.
Curaleaf’s Q2 wasn’t a flame-out like Canopy Growth’s Q1. Investors these days are far more sunnier about the former company’s prospects — the stock was among the best performers in the sector over the week, rising by 10%.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="More From The Motley Fool” data-reactid=”36″>More From The Motley Fool
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Constellation Brands. The Motley Fool has a disclosure policy.” data-reactid=”41″>Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Constellation Brands. The Motley Fool has a disclosure policy.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="This article was originally published on Fool.com” data-reactid=”42″>This article was originally published on Fool.com
Add Comment